GenFleet Therapeutics, a Shangai, China-based clinical-stage biotechnology company with a focus on therapies in oncology and immunology, closed a $75m (~500 million RMB) Series C financing.
The round was led by Huagai Capital, with participation from new investors Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital and existing investors Lake Bleu Capital, Panlin Capital, Shanjin Asset, CDH Venture and Growth Capital, HM Capital.
Led by and Dr. Jiong Lan, Co-founder and Chief Executive Officer, and Dr. Qiang Lu, Co-founder and Chairman, GenFleet Therapeutics established its proprietary R&D platform based on the deep understanding of disease biology, translational medicine, as well as researches into latest biological mechanism of cancer pathways, tumor microenvironment and human immunoregulation. Its pipeline includes over 10 products, many of which have progressed into clinical stages. As more projects move into late-stage clinical trials, GenFleet is expected to unravel its blueprint of commercialization during the next 3-5 years.